高危局限性肾细胞癌术后复发预测:影像组学临床整合模型
本研究回顾性纳入符合KEYNOTE-564标准的309例透明细胞肾细胞癌术后中高危或高危患者,基于术前CT提取影像组学特征构建影像组学签名(RS)及影像组学临床模型,主要终点为无病生存期(DFS)。RS在训练集和测试集的iAUC分别为0.78和0.72,整合临床因素后模型iAUC分别为0.81(95%CI: 0.76-0.85)和0.78(95%CI: 0.69-0.88),决策曲线分析显示其临床效用优于传统预后模型。
要点
- 影像组学临床模型可预测中高危或高危ccRCC术后DFS,测试集iAUC为0.78。
- 模型整合淋巴结状态、血管侵犯、血红蛋白和影像组学签名。
- 该工具或有助于个体化筛选辅助治疗获益人群。
核心结论
- 整合影像组学与临床因素可改善中高危或高危透明细胞肾细胞癌术后DFS预测,为个体化风险评估及辅助治疗患者筛选提供工具。
研究设计与样本
- 回顾性研究纳入309例符合KEYNOTE-564标准的透明细胞肾细胞癌术后中高危或高危患者,分为训练集247例和测试集62例。
- 从术前CT提取1316个影像组学特征,采用亲和传播聚类和随机生存森林算法构建影像组学签名(RS)。
- 采用多变量Cox回归开发影像组学临床模型,主要终点为无病生存期(DFS)。
主要发现
- RS在训练集和测试集的iAUC分别为0.78和0.72。
- 多变量分析确定淋巴结状态、血管侵犯、血红蛋白和RS为DFS预测因子(均P < .05)。
- 影像组学临床模型在训练集iAUC为0.81(95%CI: 0.76-0.85),测试集iAUC为0.78(95%CI: 0.69-0.88)。
- 决策曲线分析显示该模型临床效用优于传统预后模型。
关键数值与推荐
- RS训练集iAUC 0.78,测试集iAUC 0.72。
- 影像组学临床模型训练集iAUC 0.81(95%CI: 0.76-0.85),测试集iAUC 0.78(95%CI: 0.69-0.88)。
临床怎么用
- 对于符合KEYNOTE-564标准的中高危或高危ccRCC术后患者,可基于术前CT影像组学特征联合临床因素评估复发风险。
- 该模型或有助于识别可能从辅助免疫治疗中获益的高复发风险患者,优化个体化治疗决策。
局限性
- 本研究为回顾性研究,样本量有限,测试集仅62例。
- 模型需外部验证以确认其泛化能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant immunotherapy for clear cell renal cell carcinoma (ccRCC) is controversial because of the absence of reliable biomarkers for identifying patients most likely to benefit. The aim of this study was to develop and validate a quantitative radiomics signature (RS) and a radiomics clinical model to identify patients at increased risk of recurrence after surgery among those eligible for adjuvant immunotherapy. MATERIALS AND METHODS: This retrospective study included patients with ccRCC who are at intermediate to high risk or high risk of recurrence after nephrectomy. Inclusion criteria were patients with baseline characteristics matching the KEYNOTE-564 criteria. Radiomics texture features were extracted from preoperative CT scans. Affinity propagation clustering and random survival forest algorithms were applied to construct the RS. A radiomics clinical model was developed using multivariable Cox regression. The primary end point was disease-free survival (DFS). Model performance was assessed using time-dependent and integrated AUCs (iAUCs) and compared with conventional prognostic models using decision curve analysis. RESULTS: A total of 309 patients were included, split into training (247) and test (62) sets. From each patient, 1316 radiomics features were extracted. The RS achieved an iAUC of 0.78 in the training set and 0.72 in the test set. Multivariable analysis identified node status, vascular invasion, hemoglobin, and the RS as predictors of DFS (all P < .05). These factors formed the radiomics clinical model, which achieved an iAUC of 0.81 (95% CI: 0.76-0.85) in the training set and 0.78 (95% CI: 0.69-0.88) in the test set. Decision curve analysis demonstrated its superior clinical utility compared with conventional prognostic models. CONCLUSIONS: Integrating radiomics with clinical factors improves DFS prediction in intermediate-to-high-risk or high-risk ccRCC. This model offers a tool for individualized risk assessment, potentially optimizing patient selection for adjuvant therapy.
引用
- Khene ZE, Bhanvadia R, Tachibana I, et al. Predicting Recurrence After Surgical Resection for High-Risk Localized Renal Cell Carcinoma: A Radiomics Clinical Integration Approach. J Urol. 2025. PMID: 40294223. doi:10.1097/JU.0000000000004588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。